TUCSON, Ariz., Nov. 18, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark for its VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. This is the first ...
(RTTNews) - Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, which identifies ovarian cancer patients eligible for ...
The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRÉ‘), which is over-expressed in most ovarian cancers. The test identifies ovarian cancer patients eligible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results